Trial Profile
A Phase II Study With a Limited Safety Lead-In of Enzalutamide in Combination With Carboplatin and Paclitaxel in Advanced Stage or Recurrent Endometrioid Endometrial Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 18 Oct 2023
Price :
$35
*
At a glance
- Drugs Enzalutamide (Primary) ; Carboplatin; Paclitaxel
- Indications Endometrial cancer
- Focus Adverse reactions; Therapeutic Use
- 12 Oct 2023 Status changed from active, no longer recruiting to completed.
- 11 Aug 2023 Planned primary completion date changed from 30 Nov 2022 to 30 Nov 2023.
- 02 Nov 2021 Status changed from recruiting to active, no longer recruiting.